Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
1999-11-02
2001-09-11
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C514S171000, C514S174000, C514S653000, C514S826000
Reexamination Certificate
active
06287540
ABSTRACT:
FIELD OF THE INVENTION
The present invention provides a new pharmaceutical formulation, its preparation and its use.
BACKGROUND TO THE INVENTION
Potent drugs for administration by inhalation are generally formulated in association with carriers such as lactose because of the problem of preparing accurate doses. When such drugs are diluted, variations in the weight of the formulation result in a smaller drug dosage rate compared with when they are not diluted. These formulations have generally consisted of coarse particles of the carrier with fine particles of the drug, which combination is generally known as an ordered mixture.
The invention provides an improved formulation which, in systems designed to imitate inhalation has been found to give an improved dispersion of the drug.
DESCRIPTION OF THE INVENTION
According to the invention there is provided a dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml, preferably from 0.30 to 0.36 g/ml. The poured bulk density according to the present invention is measured using known techniques, for example those described in “Powder testing guide: Methods of measuring the physical properties of Bulk powders” L. Svarovsky, Elsevier Applied Science 1987, pp 84-86.
A potent pharmaceutically active substance suitable for use in the invention is, for example, an antiarrhythmic drug, tranquilizer, cardiac glycoside, hormone, hypertensive drug, antidiabetic or anticancer drug, sedative or analgesic drug, antibiotic, antirheumatic drug, immunotherapy, antifungal or antihypotension drug, vaccine, antiviral drug, protein (e.g. insulin), peptide, vitamin, or a cell surface receptor blocker. It is preferably a glucocorticosteroid, particularly one which is metabolized rapidly, for example beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, budesonide, rofleponide or derivatives thereof, momethasone, tipredane, RPR 106541 and/or a &bgr;2-agonist such as terbutaline, salbutamol, formoterol, salmeterol, TA 2005, pircumarol or a pharmaceutically acceptable salt thereof; and/or a prophylactic agent such as sodium chromoglycate or nedocromil sodium.
Suitable physiologically acceptable salts include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulphate, phosphate, maleate, fumarate, tarrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate or oleate salts or solvates thereof.
The carrier substance is preferably a mono-, di- or polysaccharide, a sugar alcohol or another polyol. Suitable carriers are, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. Lactose is particularly preferred, especially in the form of its monohydrate.
The ingredients of the formulation according to the invention must both be in a finely divided form, i.e. their mass median diameter should generally be less than 10 &mgr;m, preferably from 1 to 7 &mgr;m, as measured by a laser diffraction instrument or a coulter counter. The ingredients may be produced in the desired particle size using methods known to those of skill in the art, e.g. milling, micronization or direct precipitation.
The combination of budesonide and formoterol is particularly preferred. Formoterol is preferably used in the form of its fumarate, especially the dihydrate.
When the one or more potent pharmaceutically active substances used in the invention are formoterol and budesonide, the molar ratio of formoterol to budesonide in the composition of the invention is preferably from 1:2500 to 12:1, more preferably from 1:555 to 2:1, most preferably from 1:133 to 1:6. The composition according to the invention is preferably formulated to provide a daily dose of formoterol of from 2 to 120 nmol (more preferably from 7 to 70 nmol). When formoterol is used in the form of formoterol fumarate dihydrate, the composition is preferably formulated to provide a daily dose of formoterol fumarate dihydrate of from 1 to 50 &mgr;g, more preferably from 3 to 30 &mgr;g. The composition according to the invention is preferably formulated to provide a daily dose of budesonide of from 45 to 2200 &mgr;g, more preferably from 65 to 1700 &mgr;g.
More preferably the composition of the invention comprises, as a unit dose, 6 &mgr;g of formoterol fumarate dihydrate and 100 &mgr;g of budesonide, or 4.5 &mgr;g of formoterol fumarate dihydrate and 80 &mgr;g of budesonide, either of which can be administered up to four times a day. Alternatively the composition of the invention comprises, as a unit dose, 12 &mgr;g of formoterol fumarate dihydrate and 200 &mgr;g of budesonide, or 9 &mgr;g of formoterol fumarate dihydrate and 160 &mgr;g of budesonide, either of which is administered once or twice a day. Most preferably the composition used in the invention comprises, as a unit dose, 6 &mgr;g of formoterol fumarate dihydrate and 200 &mgr;g of budesonide, or 4.5&mgr;g of formoterol fumarate dihydrate and 160 &mgr;g of budesonide, either of which is administered up to four times a day. Alternatively the composition of the invention comprises, as a unit dose, 12 &mgr;g of formoterol fumarate dihydrate and 400 &mgr;g of budesonide, or 9 &mgr;g of formoterol fumarate dihydrate and 320 &mgr;g of budesonide, either of which is administered once or twice a day.
According to the invention there is further provided a process for preparing a composition according to the invention which comprises
(a) micronizing the one or more potent pharmaceutically active substances and the carrier substance;
(b) optionally conditioning the product; and
(c) spheronizing until the desired bulk density is obtained.
The process preferably rher comprises a low energy remicronization step after step (b).
The formulation according to the invention may be made by conventional techniques known per se. Such production processes generally comprise micronizing the ingredients to the required size, removing any amorphous areas on the particles obtained by, for example, the methods described in WO 92/18110 or WO 95/05805 and then agglomerating, spheronizing and sieving the powder obtained. The size of the agglomerates obtained is preferably in the range of from 100 to 2000 &mgr;m, more preferably is from 100 to 800 &mgr;m. The bulk density of the formulation produced may be adjusted by varying the components and the process empirically, for example the bulk density can be increased by lengthening the time in which the particles are tumbled in a spheronizing device.
In solid-solid mixing, one of the most important features is to ensure content uniformity. The major problem encountered in the powder mixing of fine powders is the inability of mixers to break down powder agglomerates. It has been found that a remicronization step after the conditioning step of the fine powder with low energy input is advantageous. It should generally be carried out using enough energy to break down powder agglomerates but not with so much energy that the size of the particles themselves is affected. Such a step gives a composition wherein the active substance and carrier substance are substantially uniformly distributed, having for example a relative standard deviation of less than 3% (preferably less than 1%) and does not disturb the crystallinity of the fine particles.
The formulation according to the invention may be administered using any known dry powder inhaler, for example the inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler, for example Turbuhaler (trade mark). The invention further provides use of a composition according to the invention in the manufacture of a medicament for use in therapy. Th
Astra Aktiebolag
Fish & Richardson P.C.
Weddington Kevin E.
LandOfFree
Formulation for inhalation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation for inhalation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation for inhalation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2524214